MA31412B1 - Polymorphe du bromure de (r)-3(2-hydroxy-2,2 diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2] octane - Google Patents
Polymorphe du bromure de (r)-3(2-hydroxy-2,2 diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2] octaneInfo
- Publication number
- MA31412B1 MA31412B1 MA31715A MA31715A MA31412B1 MA 31412 B1 MA31412 B1 MA 31412B1 MA 31715 A MA31715 A MA 31715A MA 31715 A MA31715 A MA 31715A MA 31412 B1 MA31412 B1 MA 31412B1
- Authority
- MA
- Morocco
- Prior art keywords
- azonia
- ylcarbamoyl
- isoxazol
- acetoxy
- bicyclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE FORME CRISTALLINE POLYMORPHE INNOVANTE DU BROMURE DE (R)-3-(2-HYDROXY-2,2-DIPHÉNYL-ACÉTOXY)-1-(ISOXAZOL- 3-YLCARBAMOYL- MÉTHYL)-1-AZONIA- BICYCLO- [2.2.2] OCTANE, APPELÉE FORME CRISTALLINE TALPHA. L'INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DE LADITE FORME CRISTALLINE ET L'UTILISATION DE LA FORME CRISTALLINE EN TANT QUE MATIÈRE ACTIVE DE MÉDICAMENTS DESTINÉS AU TRAITEMENT DE MALADIES INFLAMMATOIRES OU DE MALADIES OBSTRUCTIVES DES VOIES RESPIRATOIRES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06119883A EP1900737A1 (fr) | 2006-08-31 | 2006-08-31 | Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31412B1 true MA31412B1 (fr) | 2010-06-01 |
Family
ID=37685707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31715A MA31412B1 (fr) | 2006-08-31 | 2009-03-13 | Polymorphe du bromure de (r)-3(2-hydroxy-2,2 diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2] octane |
Country Status (21)
Country | Link |
---|---|
US (1) | US20090264461A1 (fr) |
EP (2) | EP1900737A1 (fr) |
JP (1) | JP2010501611A (fr) |
KR (1) | KR20090051110A (fr) |
CN (1) | CN101506205A (fr) |
AR (1) | AR062582A1 (fr) |
AU (1) | AU2007291515A1 (fr) |
BR (1) | BRPI0716205A2 (fr) |
CA (1) | CA2660983A1 (fr) |
CL (1) | CL2007002524A1 (fr) |
GT (1) | GT200900044A (fr) |
IL (1) | IL196808A0 (fr) |
MA (1) | MA31412B1 (fr) |
MX (1) | MX2009002300A (fr) |
NO (1) | NO20091231L (fr) |
PE (1) | PE20080985A1 (fr) |
RU (1) | RU2009111390A (fr) |
TN (1) | TN2009000069A1 (fr) |
TW (1) | TW200817399A (fr) |
WO (1) | WO2008025541A1 (fr) |
ZA (1) | ZA200900449B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
DK2091537T3 (da) * | 2006-11-23 | 2013-08-26 | Sinoxa Pharma Gmbh | Farmaceutiske sammensætninger til behandlingen af kapillær arteriopati |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
-
2006
- 2006-08-31 EP EP06119883A patent/EP1900737A1/fr not_active Ceased
-
2007
- 2007-08-28 PE PE2007001164A patent/PE20080985A1/es not_active Application Discontinuation
- 2007-08-29 CN CNA2007800314914A patent/CN101506205A/zh active Pending
- 2007-08-29 US US12/438,999 patent/US20090264461A1/en not_active Abandoned
- 2007-08-29 BR BRPI0716205-7A2A patent/BRPI0716205A2/pt not_active Application Discontinuation
- 2007-08-29 JP JP2009525978A patent/JP2010501611A/ja active Pending
- 2007-08-29 WO PCT/EP2007/007560 patent/WO2008025541A1/fr active Application Filing
- 2007-08-29 AR ARP070103830A patent/AR062582A1/es unknown
- 2007-08-29 KR KR1020097006532A patent/KR20090051110A/ko not_active Application Discontinuation
- 2007-08-29 MX MX2009002300A patent/MX2009002300A/es not_active Application Discontinuation
- 2007-08-29 EP EP07801981A patent/EP2064210A1/fr not_active Withdrawn
- 2007-08-29 RU RU2009111390/04A patent/RU2009111390A/ru not_active Application Discontinuation
- 2007-08-29 AU AU2007291515A patent/AU2007291515A1/en not_active Abandoned
- 2007-08-29 CA CA002660983A patent/CA2660983A1/fr not_active Abandoned
- 2007-08-30 CL CL200702524A patent/CL2007002524A1/es unknown
- 2007-08-30 TW TW096132302A patent/TW200817399A/zh unknown
-
2009
- 2009-01-20 ZA ZA200900449A patent/ZA200900449B/xx unknown
- 2009-01-29 IL IL196808A patent/IL196808A0/en unknown
- 2009-02-27 GT GT200900044A patent/GT200900044A/es unknown
- 2009-02-27 TN TN2009000069A patent/TN2009000069A1/fr unknown
- 2009-03-13 MA MA31715A patent/MA31412B1/fr unknown
- 2009-03-24 NO NO20091231A patent/NO20091231L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2064210A1 (fr) | 2009-06-03 |
ZA200900449B (en) | 2010-01-27 |
MX2009002300A (es) | 2009-03-20 |
KR20090051110A (ko) | 2009-05-20 |
TW200817399A (en) | 2008-04-16 |
AR062582A1 (es) | 2008-11-19 |
EP1900737A1 (fr) | 2008-03-19 |
RU2009111390A (ru) | 2010-10-10 |
AU2007291515A1 (en) | 2008-03-06 |
IL196808A0 (en) | 2009-11-18 |
JP2010501611A (ja) | 2010-01-21 |
TN2009000069A1 (en) | 2010-08-19 |
NO20091231L (no) | 2009-03-25 |
US20090264461A1 (en) | 2009-10-22 |
BRPI0716205A2 (pt) | 2013-11-12 |
CL2007002524A1 (es) | 2008-07-11 |
CN101506205A (zh) | 2009-08-12 |
GT200900044A (es) | 2012-01-16 |
WO2008025541A1 (fr) | 2008-03-06 |
PE20080985A1 (es) | 2008-09-05 |
CA2660983A1 (fr) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
BRPI0410711A (pt) | novos compostos | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
US20070248590A1 (en) | Modulators of CDC2-like kinases (CLKS) and methods of use thereof | |
MA30221B1 (fr) | Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments | |
MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
MA33365B1 (fr) | Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2 | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
NO20081212L (no) | Xantinderivater som selektive HM74A agonister | |
NO20072548L (no) | Xantinderivater med HM74A reseptoraktivitet | |
MA32787B1 (fr) | Peptides antiviraux therapeutiques | |
EA200300713A1 (ru) | Производные бензимидазола и пиридилимидазола в качестве лигандов рецепторов гамма-аминомасляной кислоты | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MA31245B1 (fr) | Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci | |
WO2007062999A3 (fr) | Derives de indole-2-yl amide substitues en 1,5 | |
ATE495171T1 (de) | Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors | |
EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
NO20022095L (no) | Heterocyklisk substituerte pyrazoloner | |
MA30337B1 (fr) | Anticorps | |
BRPI0618381A2 (pt) | processo para a preparação do hemi-sal de cálcio do ácido (3r, 5r) -7-[2-(4-fluorofenil) -5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico | |
MA30289B1 (fr) | Dérivés d'amines | |
MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
TW200740787A (en) | (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones |